Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
How does SUPREMO alter your recommendations for PMRT?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
How do you advise women to manage wound care for breast brachytherapy needle sites for long term cosmetic outcomes?
Would you consider 5-fraction whole breast RT for a patient with multiple positive margins following lumpectomy for whom reexcision is not possible?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Is ultrahypofractionation appropriate for a B51 candidate receiving breast-only radiation?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
How do you manage symptomatic fat necrosis following adjuvant breast radiotherapy?
